Sanofi

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers

A judge in Hawaii on Monday ordered Bristol-Myers Squibb Co and Sanofi SA to pay more than $834 million to the state for failing to warn non-white patients properly of health risks from its blood thinner Plavix.

Bristol-Myers, Sanofi ordered to pay Hawaii $834 million over Plavix warning label

A COVID-19 vaccine candidate developed by Sanofi and U.S. group Translate Bio "will not be ready this year," the French drugmaker's chief executive told Le Journal du Dimanche newspaper.

Sanofi's mRNA COVID-19 vaccine candidate not ready this year, CEO says

Growth of revenues and profitability have returned, with impressive leaps in cash generation. A true dividend aristocrat with 27 years of dividend increases.

Sanofi: Revival Of Fortunes

Sanofi SA (NASDAQ: SNY) has launched a takeover offer for Kiadis Pharma NV (OTC: KIADF) to represent an aggregate adjusted equity value of €308 million. The takeover offer is priced at €5.45 per share in cash.

Sanofi Offers Cash Buyout For Kiadis

This is a joint press release by Sanofi Foreign Participations B.V. (the “Offeror”), Sanofi (“Sanofi”) and Kiadis Pharma N.V. (“Kiadis”), pursuant to the provisions of Article 4 paragraph 1, Article 10 paragraph 1 and 3, and Article 18 paragraph 3 of the Netherlands Decree in Public Takeover Bids (Besluit openbare biedingen Wft, the “Decree”) in connection with the intended public offer by the Offeror for all the issued and outstanding ordinary shares in the capital of Kiadis (the “Offer”). This announcement does not constitute an offer, or any solicitation of any offer, to buy or subscribe for any securities. Any offer will be made only by means of the offer memorandum dated 10 February 2021 (the “Offer Memorandum”), approved by the Dutch Authority for the Financial Markets (Autoriteit Financiële Markten, the “AFM”) on 10 February 2021 and recognized by the Belgian Authority for the Financial Markets (Autoriteit voor Financiële Diensten en Markten) on [11 February 2021], and which is available as of today. This announcement is not for release, publication or distribution, in whole or in part, in or into, directly or indirectly, any jurisdiction in which such release, publication or distribution would be unlawful.

Sanofi launches recommended cash offer for all shares in Kiadis

Regeneron Pharmaceuticals

The FDA approves Sanofi (SNY)/Regeneron's Libtayo for treating patients with advanced/metastatic basal cell carcinoma. The is the second approved indication for the drug in the United States.

Sanofi (SNY)/Regeneron's Libtayo Gets FDA Nod for 2nd Indication

Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) immunotherapy Libtayo (cemiplimab-rwlc) has scored approval from the FDA for the treatment of advanced basal cell carcinoma (BCC), the most common type of skin cancer in the U.S. The FDA has indicated Libtayo for treating previously-treated, advanced BCC patients who have already received a hedgehog pathway inhibitor (HHI) or who cannot be treated with an HHI.

Sanofi/Regeneron's Libtayo Wins FDA Approval For A Type Of Skin Cancer

Sanofi (SNY) CEO Paul Hudson on Q4 2020 Results & Capital Markets Day (Transcript)

Sanofi's (SNY) Q4 earnings and sales miss estimates. Dupixent drives sales growth in the quarter

Sanofi (SNY) Q4 Earnings & Sales Miss, 2021 EPS View Bright

The French drug company posted better-than-expected fourth-quarter earnings on Friday and said it was targeting further cost cuts.

Sanofi Ramps Up Cost-Cutting as Earnings Beat Estimates. The Stock Is Rising.

Shares of Sanofi (NASDAQ:SNY) rose 2.7% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 3.33% over the past year to $1.45, which may not compare to the estimate of $0.69.

Sanofi: Q4 Earnings Insights

Sanofi SA (NASDAQ: SNY) posted a profit for the fourth quarter of 2020 at €1.08 billion, a turnaround from a loss of €10 million a year ago. However, sales came at €9.38 billion, down 2.4% year-over-year on a reported basis.

Sanofi Swings To Forth Quarter Profit Despite Lower Sales; Expands Cost-Savings Push By €500M

Capital Markets Day 2021: Sanofi progresses on its strategy to drive growth across its businesses and innovation with emerging leadership in immunology

Q4 2020 sales growth(2) of 4.2% and business EPS growth of 9.8% at CER

Sanofi delivered close to double-digit Q4 2020 business EPS(1) growth at CER

Sanofi (SNY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Earnings Season Could Be Great for Sanofi (SNY)

Other big firms with no Covid-19 vaccine of their own may plan on helping manufacture competitors' vaccines, analysts say.

Sanofi Will Make Pfizer's Covid-19 Vaccine. Are More Partnerships Coming?

Biogen

British American Tobacco

GlaxoSmithKline

Imperial Brands PLC

Lockheed Martin

Altria

Merck

Roche Holding AG

Our three-step process focuses on wide-moat stocks (as per Morningstar's rating).

Wide-Moat Stocks On Sale - The February 2021 Heat Map

BioNTech SE

Sanofi (SNY) to support manufacturing and supply of BioNTech's COVID-19 vaccine candidate, which the latter has developed in partnership with Pfizer.

Sanofi (SNY) to Manufacture BioNTech's Coronavirus Vaccine

Pfizer

Unusual collaboration will see Sanofi supply more than 125 million doses of Pfizer–BioNTech COVID shot from the summer.

Sanofi teams up with BioNTech and Pfizer to help fix Europe's vaccine shortage

French drug maker Sanofi SA will manufacture 125 million doses of the COVID-19 vaccine co-developed by Pfizer Inc and BioNTech SE in its Frankfurt plant starting this summer.

Sanofi To Manufacture 125 Million COVID-19 Vaccine Doses For Rival Pfizer-BioNTech

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l'Autorité des Marchés Financiers (Regulation of the French stock market authority)

Sanofi: Information concerning the total number of voting rights and shares - December 2020

Capgemini SE

Orange

Sanofi, Capgemini, Generali and Orange announce the creation of a digital ecosystem dedicated to e-health, a first in Europe

Press Release// Sanofi, Capgemini, Generali and Orange announce the creation of a digital ecosystem dedicated to e-health, a first in Europe

Sanofi is a big pharma company trading at a low valuation and paying a 3.5% dividend. Dupixent and flu vaccine sales growth boosted revenue in the latest quarter and the deep drug pipeline is impressive.

Sanofi: Big Pharma Turnaround Trading At A Discount

Total

Unilever

Vanguard FTSE Europe ETF

Part 2 of the series will search the European market for value. Sanofi is a big pharma company trading at a low valuation and paying a 3.5% dividend.

Finding Value As We Near A Possible End To The Bull Market: European Markets

Sanofi recently announced that it is going to buy Kymab. These are the details.

News for Sanofi Stock (SNY)